ICON, Tigermed Enter China Alliance

ICON and Tigermed Consulting, a provider of clinical drug development services in China, have signed an alliance agreement. The two companies will collaborate to offer clients better access to Chinese patients using ICON’s experience and global reach along with Tigermed’s knowledge of the Chinese drug development landscape and geographic coverage in China. Tigermed, headquartered in Shanghai, has 21 offices in China and more than 300 clinical development staff.

“Tigermed has a substantial clinical operations presence on the Chinese mainland and this experience, gives them the ability to provide wide-ranging support for clinical drug development in China,” commented Dr. John Hubbard, group president, Global Clinical Research Services at ICON. “TigerMed’s strength in China, complements ICON’s strong regional presence in Asia Pacific and makes them the ideal partner for ICON as we continue to drive the rapid and effective development of our client’s global drug development portfolios.”

“We are extremely pleased to have signed this agreement with ICON,” said Xiaoping Ye, chairman and chief executive officer of Tigermed. “Not only is ICON recognized as a truly global provider of quality clinical services, their culture and core values built around people, performance and client focus fit well with those of Tigermed. This alliance enhances our regional and global capabilities and will enable both ICON and Tigermed to expand the range of clinical research services we can offer to clients in China and around the globe.”